Ability Pharmaceuticals
Ability Pharmaceuticals is a Catalan biopharmaceutical company developing innovative oral autophagy-inducing anticancer compounds. Their lead compound, ABTL0812, is in a Phase 2b clinical trial for metastatic pancreatic cancer, aiming to demonstrate superior efficacy to standard treatments. The company seeks to make ABTL0812 available to patients by 2028.
Funding Round:
Funding Amount: €7M
Date: 11-Mar-2024
Investors: CTI Life Sciences Fund, Inveready, EIC Fund, Fitalent, CDTI Innvierte, family offices, founders
Markets: Biopharmaceutical, Oncology, Pharmaceutical
HQ: Barcelona, Catalonia, Spain
Founded:
Website: https://www.abilitypharma.com/
Leave a Comment
Comments
No comments yet.